亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。

返回搜索結果

A Novel Target for the Neutralization of Cancer Stem Cells in Glioblastoma

技術優勢: May increase efficacy of GBM treatmentsNon-toxic to healthy cells; reduces comorbiditiesTargets slow-dividing stem cells as opposed to rapid-dividing cells (i.e. chemotherapies)

詳細技術說明: Glioblastoma (GBM) is the most common, aggressive, and lethal primary brain tumor in adults. Currently, only four drugs are approved for GBM treatment. The current standard of care drug for GBM, Temozolomide, provides a limited survival advantage of less than 3 months, even when with combined surgical and radiation therapies. Furthermore, standard therapy is highly toxic to healthy cells. In GBM, cancer stem cells are associated with chemotherapy resistance and tumor recurrence. The increased proliferation of the cancer stem cell population is a prognostic marker for disease progression and poor clinical outcome; however, few therapeutic strategies target cancer stem cell self-renewal. UCI scientists have discovered a novel mechanism that can be exploited to regulate cancer stem maintenance and renewal to treat GBM, and may provide a promising approach to increase the overall efficacy of GBM treatment modalities.

*Abstract: Researchers at UC Irvine have recently discovered a novel mechanism that can be exploited to disrupt the maintenance and self-renewal capacity of cancer stem cells. This finding has therapeutic implications for the treatment of Glioblastoma Multiforme (GBM), which is the most common, aggressive and lethal primary brain tumor.

*Principal Investigation: Name: Aileen Anderson
Department:

Name: Francisca Benavente
Department:

其他: State Of Development
· Ongoing and future plans include:
o Development of a neutralizing antibody to target cancer stem cell renewal in vivo
o Test efficacy of combined neutralizing antibody with Temozolomide
o Evaluation of therapeutic candidate in vitro and in vivo

Tech ID/UC Case
29238/2017-888-0

Related Cases
2017-888-0

欲了解更多信息，請點擊這裡